Denali Therapeutics, Inc. (DNLI)
19.62
+0.20
(+1.03%)
USD |
NASDAQ |
Apr 14, 09:46
Denali Therapeutics Cash from Investing (TTM) : 255.28M for Dec. 31, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Neurocrine Biosciences, Inc. | -264.40M |
| Protalix Biotherapeutics, Inc. | -2.366M |
| Biogen, Inc. | -1.371B |
| Agenus, Inc. | 1.194M |
| Curis, Inc. | 2.50M |